Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.

Slides:



Advertisements
Similar presentations
Parallel Session on Monitoring and Evaluation to Inform Action and Set Direction fro Research Five -Year (5YE) Evaluation of the Global Fund Tuesday, 18.
Advertisements

The Effectiveness of Global Health Partnerships Findings and Lessons from a World Bank Evaluation of Global Health Programs Uma Lele April 14, 2005.
Karin Weyer WHO Stop TB Department Stop TB Partnership Global Laboratory Initiative.
PPM-DOTS in Cambodia Working with Private Pharmacies DOTS Expansion WG Meeting Paris 15 th October 2008 Dr. Mao Tan Eang Director National Center for TB.
Improving diagnosis TB laboratory strengthening.
Involving all health care providers in collaborative TB/HIV activities Eva Nathanson PPM subgroup meeting Cairo, Egypt, 3-5 June 2008.
The Global Laboratory Initiative Assisting countries to implement the WHA resolution on MDR-TB Karin Weyer, WHO-STB, GLI secretariat John Ridderhof, CDC,
February Dakar, Senegal
Overview of the Global Fund: Guiding Principles Grant Cycle / Processes & Role of Public Private Partnerships Johannesburg, South Africa Tatjana Peterson,
GUIDELINES & TOOLS for HOSPITAL DOTS LINKAGE (HDL)
PARIS 21 Meeting Ghana July Challenges in health information Health Metrics Network HMN Framework and profiling tool.
MEASURE Evaluation M&E and Advocacy Tools in the response to the Emergency Declaration.
Monitoring and Evaluation of National Tuberculosis Programs Regional Workshop Kyiv, Ukraine May 23-26, 2006.
Monitoring and Evaluation Frameworks Kyiv, Ukraine May 23, 2006 MEASURE Evaluation.
Monitoring and Evaluation: Tuberculosis Control Programs
Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs Using the Compendium to Plan for Monitoring and Evaluation of NTPs.
Comprehensive M&E Systems
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Engagement strategies for Montoring & Evaluation Charlotte Colvin MEASURE Regional NTP Workshop New Delhi, India 2 February 2006 MEASURE Evaluation.
Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs.
Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.
Key Terms for Monitoring and Evaluation. Objectives Explain the difference between monitoring and evaluation. Introduce the most common M&E terms. Review.
Revised National Tuberculosis Control Programme (RNTCP)
USAID TB Technical Assistance Model June 19, 2014.
African Business Leaders on Health GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 2010 Technical Assistance.
Challenge 4: Linking TB & HIV/AIDS Programs Kayt Erdahl, Project HOPE Rodrick Nalikungwi, Project HOPE Malawi December 18, 2008.
1 TB/HIV Project in the Philippines Yumiko Yanase.
Childhood TB Subgroup of the DEWG: update on policy recommendations Robert Gie Chairperson, Childhood TB Subgroup 31 October 2006 IUATLD Symposium: from.
Program Collaboration and Service Integration: An NCHHSTP Green paper Kevin Fenton, M.D., Ph.D., F.F.P.H. Director National Center for HIV/AIDS, Viral.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
A PEPFAR Perspective Bruce Baird Struminger, MD, MA Country Director CDC Global AIDS Program, Vietnam August 9, 2009 Bali, Indonesia Funding TB/HIV activities:
Health Planning and Implementation in post-conflict Afghanistan by Laurence Laumonier-Ickx, MD November 8, 2006.
Monitoring and Evaluation Module 12 – March 2010.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) “The Role of PEPFAR in the Caribbean Region” William Conn, PEPFAR Coordinator PANCAP 15 th.
Global Trends in HIV/AIDS Monitoring and Evaluation Deborah Rugg, PhD Associate Director for Monitoring and Evaluation HHS/US Centers for Disease Control.
Japan Dr. Ismail M. Aboshama Zidan Surveillance Coordinator of NTP-Egypt Action Plan to Strengthen Laboratory Diagnostic.
HSS Bottleneck areas Thailand. HIV Governance: Law on drugs (IDUs) Lack of representation in national and local levels Lack of participation or representation.
June 30, 2010 TB Program Thailand MOPH – U.S. CDC Collaboration TB Project Implementation: Impact on NTP?
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
1 DEWG meeting October 2009 Human Resource Development for TB Control (HRD-TB) Sub Group within the DEWG of the Stop TB Partnership. Wanda Walton.
Progress and plans for PPM in the WHO Region of the Americas Fifth PPM Subgroup Meeting June, Cairo.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
Exploring financing options NATIONAL TB CONTROL OF VIETNAM.
HIV TESTING AND EXPANSION OF ART FOR TB PATIENTS, BOTTLE NECKS CHALLENGES AND ENABLERS FOR SCALE UP IN KENYA DR. JOSEPH SITIENEI, OGW NTP MANAGER - KENYA.
Monitoring and Evaluation for ACSM Charlotte Colvin, PhD TB/HIV Technical Officer PATH 23 February 2010.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Comprehensive M&E Systems: Identifying Resources to Support M&E Plans for National TB Programs Lisa V. Adams, MD E&E Regional Workshop Kiev, Ukraine May.
Third Joint Bi-Annual Review of the HIV Response in Tanzania October 2008 Assessment of Progress on Implementation of Milestones from the Second Joint.
Introducing fixed dose combination tablets into DR CONGO using the Global TB Drug Facility.
ACSM at Country Level Sub Group Meeting
Introduction to Monitoring and Evaluation. Learning Objectives By the end of the session, participants will be able to: Define program components Define.
Monitoring and Evaluation: A Review of Terms
Monitoring and Evaluation Frameworks
Key issues in DOTS implementation
Update on SBCC Activities of Challenge TB Bangladesh
Objectives of Session Provide an overview of the development of Compendium Explain the organization of the Compendium and how indicators are used Provide.
The role of the community in TB control
Vietnam Investment and Finance for TB
5th DEWG meeting Conclusions
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Presentation for Second Meeting of the Global TB/HIV Working Group
The STOP TB Strategy – 2009 VISION: A TB-free world
Surveillance, Monitoring and Evaluation Working Group
Current status – (1) Achievements Building strong political commitment
Comprehensive M&E Systems
33rd IUATLD World Conference on Lung Health
Indicator: % of population in an area of BMU implementing DOTS
Monitoring and Evaluation: A Review of Terms
Presentation transcript:

Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs

What is the Compendium? A comprehensive and standardized collection of the most widely used and recommended indicators for monitoring and evaluation of National TB Programs.

Who is it for? NTP managers, data managers, regional and district officers NGO program managers/data managers involved in TB programming Evaluation specialists Health-system planners (HMIS, etc.)  Anyone with responsibility for collecting, processing, analyzing, and presenting data on tuberculosis programs.

Specific Objectives Standardize M&E terminology across indicators and programs Encourage consistent use of indicators to monitor and evaluate programs Provide guidance for the development of comprehensive evaluation plans Serve as a resource for the different components of the monitoring and evaluation process

Why a new TB M&E Guide? (1) Patient follow-up/case management using WHO standardized forms Need for program data to guide M&E Small number of indicators focusing on outcomes of DOTS implementation Project-specific monitoring forms Periodic assessment visits at facility level

Why a new TB M&E Guide? (2) New Global Initiatives Global Fund for AIDS, TB, and Malaria STOP TB Partnership Increased USAID involvement TB/HIV initiatives DOTS Plus

INPUT Policy environment Human and Financial Resources Infrastructure PROCESS Management Training Drug management Laboratories Communication Advocacy OUTPUT Diagnostic services Treatment services Improved knowledge, attitudes, and practices Reduced stigma OUTCOME Case detection Treatment success IMPACT Prevalence of TB infection Prevalence of TB disease TB morbidity TB mortality M&E Framework for TB programs p7, Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs USAID, MEASURE, CDC, WHO, IUATLD, KNCV, MSH. WHO/HTM/TB/ , August 2004

Expansion of M&E activities Framework links inputs, processes to outputs, outcomes, impact Standardized indicators for global use Program-based to complement case management Program-specific indicators for different settings, types of programs

International M&E Guidance Provide most useful indicators for monitoring and evaluating TB control programs Encourage use of standardized definitions of indicators and terminology across programs, countries and donor agencies Provide measures of process and output linked to program activities Promote process and impact evaluation of TB control programs

INPUT Policy environment Human and Financial Resources Infrastructure PROCESS Management Training Drug management Laboratories Communication Advocacy OUTPUT Diagnostic services Treatment services Improved knowledge, attitudes, and practices Reduced stigma OUTCOME Case detection Treatment success IMPACT Prevalence of TB infection Prevalence of TB disease TB morbidity TB mortality M&E Framework for TB Programs p7, Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs USAID, MEASURE, CDC, WHO, IUATLD, KNCV, MSH. WHO/HTM/TB/ , August 2004

Compendium Development Step 1: Assessment of existing M&E systems within national TB programs and MOH Step 2: Create an international TB M&E working group to develop and review indicators Step 3: Field test indicators in selected countries Step 4: Build capacity in M&E to collect, disseminate, and use information

Step 1: Assessment of current M&E systems Field visits to examine M&E systems: data collection forms, reporting, supervision, data use South Africa, Russia, Honduras, Philippines Met with NTPs, USAID missions, WHO, CDC, local implementing partners Review of literature on TB indicators

Results from assessment visits Substantial amount of data collected at facility level that is not reported Weakness in reporting mechanisms for facility level data Few indicators on political commitment, IEC activities, drug supply and TB/HIV Lack of data from private sector physicians

Step 2: Creation of an international working group Similar goals to develop more informative indicators on program implementation Bring expertise from a wide variety of sources: Stop TB, WHO, UNION, KNCV, CDC, USAID, World Bank, MSH, MEASURE/Evaluation

Results of TB M&E Working Group Indicators for DOTS: measure key aspects of the TB epidemic in a country and the programmatic response Based on WHO recommendations and collected through existing systems External and Expert review

Step 3: Field testing Peru, Kazakhstan, Haiti, and Thailand Revision of indicators based on field-testing results Step 4: Building capacity Egypt (March), Mexico (this workshop), Cambodia (June), Sub-Saharan Africa (June) Technical assistance

Indicators (1) Global indicators (5) –Case detection –Treatment success –DOTS coverage –HIV seroprevalence among TB cases –Surveillance of MDR-TB Routinely reported program outcomes –Case detection (6) –Smear conversion –Treatment outcome

Indicators (3) Process indicators to measure DOTS implementation under expanded framework: –Political commitment (12) NTP annual work plan and budget –Diagnosis (7) Existence of comprehensive laboratory network –Case management, including DOT (2) Proportion of patients with correct prescription –Drug management (8) Existence of a quality assurance system for drug management

Indicators (3) Process indicators to measure DOTS implementation under expanded framework: –Recording & reporting (2) Accuracy of reports sent to NTP –Supervision (2) Existence of supervision guidelines –Human resources development (3) Proportion of health centers with at least one professional trained in the DOTS strategy –Health systems (1) Equitable distribution of DOTS

Conclusion Introduction to the Compendium – overview and background Next – How to use the Compendium